{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+injection&page=4", "query": { "intervention": "Insulin glargine injection", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 119, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+injection&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+glargine+injection&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T22:43:31.938Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01582451", "title": "A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2605541", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 466, "start_date": "2012-05", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2018-04-20", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 33, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01582451" }, { "nct_id": "NCT00308308", "title": "Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes, Type I" ], "interventions": [ { "name": "Technosphere Insulin", "type": "DRUG" }, { "name": "Active comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 589, "start_date": "2006-02", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2014-10-16", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 61, "location_summary": "Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Foothill Ranch", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00308308" }, { "nct_id": "NCT03751657", "title": "A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin icodec", "type": "DRUG" }, { "name": "Placebo (insulin 287)", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Dipeptidyl peptidase-4 inhibitors", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Placebo (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 247, "start_date": "2018-11-29", "completion_date": "2020-01-17", "has_results": true, "last_update_posted_date": "2021-04-02", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 14, "location_summary": "Lancaster, California • Ventura, California • Walnut Creek, California + 9 more", "locations": [ { "city": "Lancaster", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Roswell", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03751657" }, { "nct_id": "NCT00694122", "title": "Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes", "Dawn Phenomenon" ], "interventions": [ { "name": "Lantus (glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2005-06", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2014-10-21", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694122" }, { "nct_id": "NCT00975286", "title": "24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Thiazolidinedione (TZD)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 23, "location_summary": "Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain Home", "state": "Arkansas" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975286" }, { "nct_id": "NCT03687827", "title": "A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin degludec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2018-10-02", "completion_date": "2019-12-27", "has_results": true, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 34, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03687827" }, { "nct_id": "NCT00127634", "title": "Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Human Insulin Inhalation Powder", "type": "DRUG" }, { "name": "Injectable Insulin", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2005-07", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 35, "location_summary": "Sacramento, California • Walnut Creek, California • Aurora, Colorado + 32 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00127634" }, { "nct_id": "NCT00883558", "title": "Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Insulin Lispro", "type": "DRUG" }, { "name": "regular human insulin", "type": "DRUG" }, { "name": "recombinant human hyaluronidase PH20", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2009-05", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 8, "location_summary": "Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Butte", "state": "Montana" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00883558" }, { "nct_id": "NCT00384085", "title": "Insulin Glargine \"All to Target\" Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin Glulisine", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Premixed Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 588, "start_date": "2006-05", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-05-06", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384085" }, { "nct_id": "NCT03371082", "title": "Gan & Lee Insulin Glargine Target Type (1) Evaluating Research", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Gan & Lee Insulin Glargine Injection", "type": "BIOLOGICAL" }, { "name": "Lantus®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gan and Lee Pharmaceuticals, USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 576, "start_date": "2017-10-31", "completion_date": "2019-08-19", "has_results": true, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-10-14T22:43:31.938Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Tarzana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03371082" } ] }